U.S. markets closed
  • S&P 500

    4,422.30
    +10.51 (+0.24%)
     
  • Dow 30

    35,144.31
    +82.76 (+0.24%)
     
  • Nasdaq

    14,840.71
    +3.72 (+0.03%)
     
  • Russell 2000

    2,216.92
    +7.27 (+0.33%)
     
  • Crude Oil

    72.19
    +0.12 (+0.17%)
     
  • Gold

    1,797.20
    -4.60 (-0.26%)
     
  • Silver

    25.25
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1808
    +0.0038 (+0.32%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3819
    +0.0065 (+0.47%)
     
  • USD/JPY

    110.3670
    -0.1430 (-0.13%)
     
  • BTC-USD

    37,554.65
    +3,045.59 (+8.83%)
     
  • CMC Crypto 200

    905.01
    -10.48 (-1.14%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

CorMedix Inc. to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 11

BERKELEY HEIGHTS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close on Monday, May 11, and will host a corporate update conference call at 4:30pm Eastern Time.

Monday, May 11th @ 4:30pm ET

Domestic:

800-949-2175

International:

646-828-8144

Conference ID:

3381536

Webcast:

http://public.viavid.com/index.php?id=139349

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters for the U.S. market. The Company completed a Phase 3 clinical trial of Neutrolin in patients undergoing chronic hemodialysis, which showed a 71% reduction in catheter-related bloodstream infections (CRBSIs) relative to the heparin control arm (p=0.0006) with a good safety profile. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. FDA has granted rolling submission and review of portions of the new drug application (NDA) and CorMedix has begun submission of the NDA. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
617-430-7576